|Bid||44.52 x 200|
|Ask||44.95 x 300|
|Day's Range||43.62 - 44.80|
|52 Week Range||22.17 - 45.74|
|PE Ratio (TTM)||18.50|
|Dividend & Yield||0.40 (0.91%)|
|1y Target Est||N/A|
John Linehan, manager of the Bronze-rated T. Rowe Price Equity Income, has generated fine results since taking over for the retiring Brian Rogers in late 2015.
Like its rivals Cardinal Health (No. 7) and McKesson (No. 73), Amerisource has been buffeted by Wall Street’s concerns about pricing pressure on branded and generic drugs. SEE THE FULL LIST OF THE BARRON’S 500 Amerisource (ABC) “is a key cog within the pharmaceutical industry, as many other supply-chain participants are dependent upon its services for streamlined product distribution and procurement,” notes Vishnu Lekraj, a Morningstar analyst. Sales growth, as it happens, is one of three components in our annual ranking, which spotlights companies that do the best job of boosting revenue and investing for growth.